Dermatology
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Access global dermatology market intelligence, drug development trends, and regulatory insights for pharma BD, investors, and analysts.
Showing 1–8 of 8 articles
Quick answer
NovaPharmaNews Dermatology hub for FDA covers 8 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
Takeda TYK2 drug tops Bristol Myers’ Sotyktu in psoriasis head-to-head test
Nektar Therapeutics pipeline update: REZPEG, amphotericin B and UK site changes
Palvella Therapeutics Begins Phase 2 Trial of QTORIN Rapamycin for Rare Angiokeratomas
Sagimet Biosciences Plans Phase 3 Denifanstat Trial for Acne Treatment in 2026
Veradermics VDPHL01 Phase 2/3 Trial Results for Male Pattern Hair Loss to Be Announced
Veradermics VDPHL01 Phase 2/3 Trial Results: Conference Call Scheduled for Oral Minoxidil Hair Loss Treatment
Psoriasis Treatment Pipeline Explodes: 90+ Companies Race to Develop Next-Generation Therapies in 2026
FDA Approves Litfulo: Key Facts on Pfizer’s Alopecia Treatment
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.